Management of kidney cancer patients: 2018 guidelines of the Italian Medical Oncology Association (AIOM).
Clicks: 257
ID: 12876
2019
In the past two decades, the treatment landscape for patients with metastatic renal cell carcinoma has significantly changed thanks to the approval of several targeted molecular therapies (VEGF and mTOR inhibitors) and recently immune-checkpoint inhibitors. The Italian Association of Medical Oncology (AIOM) Renal Cell Cancer (RCC) Guidelines Panel has developed clinical guidelines to provide evidence-based information and recommendations to oncologists, urologists and all professionals involved in the management of patients with renal cell cancer.
| Reference Key |
vitale2019managementtumori
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Vitale, Maria Giuseppa;Bracarda, Sergio;Cosmai, Laura;Crocetti, Emanuele;Di Lorenzo, Giuseppe;Lapini, Alberto;Mandressi, Alberto;Martorana, Giuseppe;Masini, Cristina;Montironi, Rodolfo;Ortega, Cinzia;Passalacqua, Rodolfo;Porta, Camillo;Procopio, Giuseppe;Sepe, Pierangela;Romano, Luigia;Pappagallo, Giovanni Luigi;Conti, Giario;Guida, Michele;Martignoni, Guido;Nolè, Franco;Pignata, Sandro;Gori, Stefania;Cartenì, Giacomo; |
| Journal | tumori |
| Year | 2019 |
| DOI | 10.1177/0300891619853392 |
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.